原发性肝癌发病机制和药物治疗的研究进展

doi:10.3969/j.issn.1006-6233.2024.02.034

摘要
图/表
参考文献
相关文章 (15)

[1] Rumgay H,Arnold M,Ferlay J,et al.Global burden of primary liver cancer in 2020 and predictions to 2040[J].Hepatol,2022,77(6):1598-1606.
[2] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer Clin,2021,71(3):209-249.
[3] 刘小凡,谢晓磊,吴咏梅,等.卵泡刺激素对原癌基因c-myc在鸡卵泡上表达的影响[J].南京农业大学学报,2023,46(3):564-571.
[4] Xu C,Zhou W,Wang Y,et al.Hepatitis B virus-induced hepatocellular carcinoma[J].Cancer letters,2014,345(2):216-222.
[5] 翟海晖,刘元祺,张从政等.P53与肿瘤代谢的最新研究进展[J].中国癌症杂志,2023,33(11):1032-1040.
[6] 史光军,陈孝平,张万广,等.Rb基因产物与原发性肝癌的生物学特性及预后关系的研究[J].中国普通外科杂志,2003,12(9):710-712.
[7] Shi DM,Bian XY,Qin CD,et al.miR-106b-5p promotes stem cell-like properties of hepatocellular carcinoma cells by targeting PTEN via PI3K/Akt pathway[J].Onco Targets Ther,2018,(11):571-585.
[8] 贾晓晴,佟晓哲.巴西苏木素通过激活Wnt/β-catenin通路调控卵巢癌SKOV3细胞增殖、凋亡、迁移和侵袭的研究[J].中国临床药理学杂志,2023,39(9):1237-1241.
[9] Yoshikawa H,Matsubara K,Zhou X,et al.WNT10B functional dualism:beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer[J].Mol Biol Cell,2007,18(11):4292-4303.
[10] Katoh Y,Katoh M.Hedgehog target genes:mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation[J].Current molecular medicine,2009,9(7):873-886.
[11] Gramantieri L,Giovannini C,Lanzi A,et al.Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma[J].Liver Int,2007,27(7):997-1007.
[12] Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
[13] 祖亮,宋晶晶,郑丽云,等.经肝动脉化疗栓塞联合索拉非尼治疗中晚期肝癌合并肝破裂出血的有效性及安全性[J].肝胆胰外科杂志,2021,33(10):581-584,595.
[14] Hatanaka T,Kakizaki S,Nngashima T,et al.A change in the timing for starting systemic therapies for hepatocellular carcinoma:the comparison of sorafenib and lenvatinib as the first-line treatment[J].Acta Gastroenterol Belg,2021,84(1):65-72.
[15] Wilhelm SM,Dumas J,Adnane L,et al.Regorafenib (BAY 73-4506):a new oral multikinase inhibitor of angiogenic,stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J].Int Cancer,2011,129(1):245-255.
[16] 林晓纯,萧聪勤,林坤鹏.阿帕替尼联合肝动脉化疗栓塞术治疗肝癌合并门静脉癌栓的Meta分析[J].广州医科大学学报,2022,50(4):34-41.
[17] Zhu AX,Park JO,Ryoo BY,et al.Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH):a randomised,double-blind,multicentre,phase 3 trial[J].Lancet Oncol,2015,16(7):859-870.
[18] Chen ZN,Mi L,Xu J,et al.Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (¹³¹I) metuximab injection:clinical phase Ⅰ/Ⅱ trials[J].Int Radiat Oncol Biol Phys,2006,65(2):435-444.
[19] Wu L,Yang YF,Ge NJ,et al.Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma:interim safety and survival data from 110 patients[J].Cancer Biother Radiopharm,2010;25(6):657-663.
[20] Qin S,Ren Z,Meng Z,et al.Camrelizumab in patients with previously treated advanced hepatocellular carcinoma:a multicentre,open-label,parallel-group,randomised,phase 2 trial[J].Lancet Oncol,2020,21(4):571-580.
[21] 许磊,汪义纯,康梅,等.卡瑞利珠单抗联合阿帕替尼治疗原发性肝癌的疗效评估[J].中国肿瘤生物治疗杂志,2023,30(4):331-337.
[22] El-khoueiry AB,Sangro B,Yau T,et al.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J].Lancet,2017,389(10088):2492-2502.
[23] Yau T,Park JW,Finn RS,et al.Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459):a randomised,multicentre,open-label,phase 3 trial[J].Lancet Oncol,2022,23(1):77-90.
[24] Finn RS,Ryoo BY,Merle P,et al.Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240:a randomized,double-blind,phase Ⅲ trial[J].Clin Oncol,2020,38(3):193-202.
[25] Desai J,Deva S,Lee JS,et al.Phase IA/IB study of single-agent tislelizumab,an investigational anti-PD-1 antibody,in solid tumors[J].Immunother Cancer,2020,8(1):453.
[26] Qin S, Chen Z, Fang W, et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial[J].Clin Oncol, 2023,41(7):1434-1443.
[27] Lee DW, Cho EJ, Lee JH, et al. Phase II study of avelumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib[J]. Clin Cancer Res, 2021,27(3):713-718.